Development of autoantibody signatures for common cancers.
Antigen-Antibody Complex
/ immunology
Antigens, Neoplasm
/ immunology
Autoantibodies
/ genetics
Autoantigens
/ immunology
Biomarkers, Tumor
Cell Surface Display Techniques
Computational Biology
/ methods
Early Detection of Cancer
Epitope Mapping
/ methods
Epitopes
/ immunology
Humans
Neoplasms
/ diagnosis
Peptides
/ genetics
Prognosis
Proteomics
/ methods
Antigen-antibody complexes
Autoantibody
Biomarker signatures
Cancer early detection
Journal
Seminars in immunology
ISSN: 1096-3618
Titre abrégé: Semin Immunol
Pays: England
ID NLM: 9009458
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
09
10
2019
accepted:
01
01
2020
pubmed:
12
1
2020
medline:
26
11
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
A humoral immune response in the form of autoantibodies to tumor antigens occurs early during tumor development. Identification of antigens that induce an autoantibody response restricted to a cancer type has the potential to yield markers useful for early detection. A multitude of strategies are currently available for the discovery of tumor antigens directed autoantibodies in circulation. Each approach has advantages and limitations for comprehensive discovery of antigenic epitopes. Herein, we review established and novel strategies and methodologies and highlight potential cancer applications.
Identifiants
pubmed: 31924500
pii: S1044-5323(20)30004-X
doi: 10.1016/j.smim.2020.101388
pii:
doi:
Substances chimiques
Antigen-Antibody Complex
0
Antigens, Neoplasm
0
Autoantibodies
0
Autoantigens
0
Biomarkers, Tumor
0
Epitopes
0
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101388Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.